Seeking Alpha

Baird flies in the face of the Affymax (AFFY -8.1%) bloodbath, raising its price target to $17...

Baird flies in the face of the Affymax (AFFY -8.1%) bloodbath, raising its price target to $17 from $15 following the FDA's approval of its anemia drug Omontys. The firm says recent weakness was primarily due to pricing concerns but they consider the weakness a buying opportunity. Shares are currently rated Outperform.
Comments (2)
  • drekon
    , contributor
    Comments (180) | Send Message
     
    Baird's favorite moto, "recent pullback provides buying opportunity"
    28 Mar 2012, 03:30 PM Reply Like
  • geo22253
    , contributor
    Comment (1) | Send Message
     
    So when is this supposed to happen? AFFY has only gone down since yesterday.
    28 Mar 2012, 05:13 PM Reply Like
DJIA (DIA) S&P 500 (SPY)